Selank vs. semax: separating peptide hype from actual evidence

What did @pyrefitness35 actually say?

The creator drew a clean contrast between two Russian-developed peptides: Selank as the calming, anxiolytic option and Semax as the stimulating, focus-driven one. They called Semax "like a mini-Adderall" and credited it with neuroplasticity and neuroprotective effects. They also noted both can be administered nasally or subcutaneously, and pointed to their use history in Russia as a signal of future mainstream attention.

To be fair, the creator didn't make any wild dosing claims or promise cures. The framing was comparative and experiential, which is actually more responsible than a lot of peptide content floating around TikTok. That said, the "mini-Adderall" line is doing a lot of work and deserves serious scrutiny, and the neuroprotection claim needs more nuance than a 60-second video can give it.

Does the science back this up?

Partially, and with important caveats. The anxiolytic framing for Selank is the better-supported of the two characterizations. The Semax-as-stimulant framing is directionally plausible but oversimplified, and the neuroprotection claim is real but context-dependent.

Selank is a synthetic hexapeptide derived from tuftsin, developed at the Institute of Molecular Genetics in Moscow. A 2014 study by Zozulya et al. in CNS Neuroscience and Therapeutics found anxiolytic effects comparable to benzodiazepines in animal models, without the sedation or dependence risk. Human data is thin by Western standards, but the mechanistic story, modulation of GABA-A receptors and enkephalin metabolism, is coherent with a calming profile.

Semax is an ACTH(4-7) analog, also Russian in origin. Research by Gusev et al. (2018, Journal of Neurological Sciences) showed it increases BDNF and NGF expression, which supports the neuroplasticity claim. Its cognitive effects in healthy adults, however, are barely studied outside Russian clinical literature, most of which has not been independently replicated in Western trials.

What did they get wrong (or right)?

The "mini-Adderall" comparison is the most problematic line in the video. They got the direction right but the mechanism wrong. Adderall works by flooding the synapse with dopamine and norepinephrine through reuptake inhibition and forced release. Semax does not do this. Its stimulant-adjacent effects are likely downstream of BDNF upregulation and dopaminergic modulation, which is a slower, softer process, not a catecholamine surge. Calling it a mini-Adderall sets an expectation that the compound almost certainly won't meet for most people, and it minimizes the actual pharmacological distinction.

What they got right: the anxiolytic framing for Selank is defensible. The observation that both can be administered nasally is accurate and relevant, since intranasal delivery is the most studied route for both peptides. Acknowledging the Russian clinical history is fair context, though it's worth noting that Russian regulatory standards differ substantially from FDA or EMA frameworks.

• Selank's calming profile: mostly accurate
• Semax neuroplasticity claim: plausible, evidence is limited to mostly animal and Russian clinical data
• "Mini-Adderall" comparison: misleading on mechanism
• Nasal and subcutaneous routes: accurate

What should you actually know?

Neither Selank nor Semax is FDA-approved. In the United States, both exist in a gray zone, sometimes compounded by pharmacies for off-label use, sometimes sold as research chemicals. That distinction matters enormously. Compounded peptides are not equivalent to the pharmaceutical-grade versions used in Russian clinical trials, and quality control across suppliers varies widely.

The neuroprotection claim for Semax is real in the sense that it has been studied as an adjunct therapy after stroke in Russia, but that is a clinical, supervised context. Extrapolating from stroke recovery data to healthy cognitive optimization is a significant leap that the creator doesn't acknowledge.

If you're considering either compound, the honest answer is that the human evidence base is thin, the regulatory status is complicated, and the long-term safety profile in healthy adults is essentially unknown. These are interesting compounds. That doesn't mean they're ready for casual self-experimentation based on TikTok comparisons.

The bottom line

The creator gave a broadly reasonable lay summary with one significant misfire. Framing Semax as a "mini-Adderall" is catchy but mechanistically wrong, and in a category where people are making real decisions about injection protocols, that kind of shorthand carries risk. The Selank characterization holds up better. The overall tone of the video was more responsible than average for peptide content, but the gaps in what wasn't said, regulatory status, quality control, lack of robust human trials, matter as much as what was.